Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin

Human Molecular Genetics

Volumn 20, Issue 7, 2011, Pages 1290-1305

  Malhowski, Amy J ^a   Hira, Haider ^a   Bashiruddin, Sarah ^a   Warburton, Rod ^a   Goto, June ^b   Robert, Blanton ^a   Kwiatkowski, David J ^b   Finlay, Geraldine A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN S6; RAPAMYCIN; S6 KINASE; TRANSGELIN; TUBERIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EMBRYO; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENETIC RECOMBINATION; HEART DEVELOPMENT; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMEGALY; HEART; HEART DEFECTS, CONGENITAL; MICE; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MYOCYTES, CARDIAC; ORGAN SIZE; PROTEINS; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA; MUS;

EID: 79952577412     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq570     Document Type: Article

References (48)

1. The European Chromosome 16 Tuberous Sclerosis Consortium. (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell, 75, 1305-1315.
2. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J. et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277, 805-808.
3. Watson, G.H. (1991) Cardiac rhabdomyomas in tuberous sclerosis. Ann. NY Acad. Sci., 615, 50-57.
4. Lavocat, M.P., Teyssier, G., Allard, D., Tronchet, M. and Freycon, F. (1992) Abdominal aortic aneurysm and Bourneville's tuberous sclerosis. Pediatrie, 47, 517-519.
5. Li, Y., Corradetti, M.N., Inoki, K. and Guan, K.L. (2004) TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci., 29, 32-38.
6. Li, Y., Inoki, K. and Guan, K.L. (2004) Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol., 24, 7965-7975.
7. Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K.L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol., 4, 648-657.
8. Potter, C.J., Huang, H. and Xu, T. (2001) Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell, 105, 357-368.
9. Inoki, K., Ouyang, H., Li, Y. and Guan, K.L. (2005) Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev., 69, 79-100.
10. Kwiatkowski, D.J. and Manning, B.D. (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet., 14 (Spec no. 2), R251-R258.
11. Arad, M., Benson, D.W., Perez-Atayde, A.R., McKenna, W.J., Sparks, E.A., Kanter, R.J., McGarry, K., Seidman, J.G. and Seidman, C.E. (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest., 109, 357-362.
12. Ashrafian, H. and Watkins, H. (2005) Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy. Drug Discov. Today, 2, 129-134.
13. Balasubramanian, S., Johnston, R.K., Moschella, P.C., Mani, S.K., Tuxworth, W.J. Jr. and Kuppuswamy, D. (2009) mTOR in growth and protection of hypertrophying myocardium. Cardiovasc. Hematol. Agents Med. Chem., 7, 52-63.
14. Maron, B.J. (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA, 287, 1308-1320.
15. McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C., Dorfman, A.L., Longnus, S., Pende, M., Martin, K.A., Blenis, J. et al. (2004) Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol., 24, 6231-6240.
16. Shen, W.H., Chen, Z., Shi, S., Chen, H., Zhu, W., Penner, A., Bu, G., Li, W., Boyle, D.W., Rubart, M. et al. (2008) Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function. J. Biol. Chem., 283, 13842-13849.
17. Shioi, T., Kang, P.M., Douglas, P.S., Hampe, J., Yballe, C.M., Lawitts, J., Cantley, L.C. and Izumo, S. (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J., 19, 2537-2548.
18. Shioi, T., McMullen, J.R., Kang, P.M., Douglas, P.S., Obata, T., Franke, T.F., Cantley, L.C. and Izumo, S. (2002) Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol., 22, 2799-2809.
19. Zhang, D., Contu, R., Latronico, M.V., Zhang, J.L., Rizzi, R., Catalucci, D., Miyamoto, S., Huang, K., Ceci, M., Gu, Y. et al. (2010) MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest., 120, 2805-2816.
20. Li, L., Miano, J.M., Cserjesi, P. and Olson, E.N. (1996) SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ. Res., 78, 188-195.
21. Soriano, P. (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet., 21, 70-71.
22. Cao, J., Gong, L., Guo, D.C., Mietzsch, U., Kuang, S.Q., Kwartler, C.S., Safi, H., Estrera, A., Gambello, M.J. and Milewicz, D.M. (2010) Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. Hum. Mol. Genet., 19, 1908-1920.
23. Shepherd, C.W., Gomez, M.R., Lie, J.T. and Crowson, C.S. (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc., 66, 792-796.
24. Fingar, D.C., Richardson, C.J., Tee, A.R., Cheatham, L., Tsou, C. and Blenis, J. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol., 24, 200-216.
25. Fingar, D.C., Salama, S., Tsou, C., Harlow, E. and Blenis, J. (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev., 16, 1472-1487.
26. Huang, J., Dibble, C.C., Matsuzaki, M. and Manning, B.D. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol., 28, 4104-4115.
27. Huang, J. and Manning, B.D. (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J., 412, 179-190.
28. Zhang, H., Cicchetti, G., Onda, H., Koon, H.B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C.L. and Kwiatkowski, D.J. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest., 112, 1223-1233.
29. Ikeda, Y., Sato, K., Pimentel, D.R., Sam, F., Shaw, R.J., Dyck, J.R. and Walsh, K. (2009) Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J. Biol. Chem., 284, 35839-35849.
30. Inoki, K., Zhu, T. and Guan, K.L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590.
31. Meikle, L., McMullen, J.R., Sherwood, M.C., Lader, A.S., Walker, V., Chan, J.A. and Kwiatkowski, D.J. (2005) A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum. Mol. Genet., 14, 429-435.
32. Crespo-Leiro, M.G. and Hermida-Prieto, M. (2008) Sirolimus treatment of left ventricular hypertrophy: who, and when?. Eur. Heart J., 29, 2703-2704.
33. Gao, X.M., Wong, G., Wang, B., Kiriazis, H., Moore, X.L., Su, Y.D., Dart, A. and Du, X.J. (2006) Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J. Hypertens., 24, 1663-1670.
34. Kushwaha, S.S., Raichlin, E., Sheinin, Y., Kremers, W.K., Chandrasekaran, K., Brunn, G.J. and Platt, J.L. (2008) Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur. Heart J., 29, 2742-2750.
35. McMullen, J.R., Sherwood, M.C., Tarnavski, O., Zhang, L., Dorfman, A.L., Shioi, T. and Izumo, S. (2004) Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation, 109, 3050-3055.
36. Soesanto, W., Lin, H.Y., Hu, E., Lefler, S., Litwin, S.E., Sena, S., Abel, E.D., Symons, J.D. and Jalili, T. (2009) Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension, 54, 1321-1327.
37. Siedlecki, A.M., Jin, X. and Muslin, A.J. (2009) Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int., 75, 800-808.
38. Jozwiak, S., Kotulska, K., Kasprzyk-Obara, J., Domanska-Pakiela, D., Tomyn-Drabik, M., Roberts, P. and Kwiatkowski, D. (2006) Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics, 118, e1146-e1151.
39. Hernando, E., Charytonowicz, E., Dudas, M.E., Menendez, S., Matushansky, I., Mills, J., Socci, N.D., Behrendt, N., Ma, L., Maki, R.G. et al. (2007) The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med., 13, 748-753.
40. Kozlowski, P., Roberts, P., Dabora, S., Franz, D., Bissler, J., Northrup, H., Au, K.S., Lazarus, R., Domanska-Pakiela, D., Kotulska, K. et al. (2007) Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum. Genet., 121, 389-400.
41. Finlay, G.A., Malhowski, A.J., Polizzi, K., Malinowska-Kolodziej, I. and Kwiatkowski, D.J. (2009) Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol. Cancer Ther., 8, 1799-1807.
42. Finlay, G.A., York, B., Karas, R.H., Fanburg, B.L., Zhang, H., Kwiatkowski, D.J. and Noonan, D.J. (2004) Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of PDGFR-beta and ERK-1/2. J. Biol. Chem., 23, 23.
43. Lueck, A., Brown, D. and Kwiatkowski, D.J. (1998) The actin-binding proteins adseverin and gelsolin are both highly expressed but differentially localized in kidney and intestine. J. Cell Sci., 111, 3633-3643.
44. Hill, N.S., Klinger, J.R., Warburton, R.R., Pietras, L. and Wrenn, D.S. (1994) Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am. J. Physiol., 266, L308-L315.
45. Klinger, J.R., Warburton, R.R., Pietras, L., Oliver, P., Fox, J., Smithies, O. and Hill, N.S. (2002) Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol., 282, H58-H65.
46. Sahn, D.J., DeMaria, A., Kisslo, J. and Weyman, A. (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation, 58, 1072-1083.
47. Calderone, A., Thaik, C.M., Takahashi, N., Chang, D.L. and Colucci, W.S. (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest., 101, 812-818.
48. Sadoshima, J., Jahn, L., Takahashi, T., Kulik, T.J. and Izumo, S. (1992) Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J. Biol. Chem., 267, 10551-10560.